[18F]MFBG PET/CT outperforming [123I]MIBG SPECT/CT in the evaluation of neuroblastoma

Wang, Peipei; Li, Tuo; Liu, Zhikai; Jin, Mei; Su, Yan; Zhang, Jingjing; Jing, Hongli; Zhuang, Hongming; Li, Fang

doi:10.1007/s00259-023-06221-4

Cited by 15 publications

(19 citation statements)

References 37 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…PET/CT technology generally has higher resolution and accuracy than conventional nuclear medicine technique. 18 F-MFBG PET/CT has been reported to be useful in the evaluation of neuroblastoma 10,11 and pheochromocytoma/paragangliomas 12–15 . Our case indicated that dynamic PET/CT using 18 F-MFBG or possible other PET tracer holds potential as a diagnostic tool for better evaluating GERD.…”

mentioning

confidence: 68%

Gastroesophageal Reflux Revealed by 18F-MFBG PET/CT

He,

Yang,

et al. 2024

Clin Nucl Med

View full text Add to dashboard Cite

A 56-year-old woman who had a lung transplant 4 months ago presented frequent vomiting for 1 month. Barium meal and 99mTc gastroesophageal scintigraphy showed no gastroesophageal reflux. The patient was enrolled in a clinical trial and underwent 18F-MFBG PET/CT dynamic imaging. At the seventh minute of dynamic imaging, the images revealed reflux from the cardia into the esophagus and reached the oral cavity.

show abstract

mentioning

confidence: 68%

Gastroesophageal Reflux Revealed by 18F-MFBG PET/CT

He,

Yang,

et al. 2024

Clin Nucl Med

View full text Add to dashboard Cite

show abstract

“…Initial studies report that MIBG PET/ CT has a higher lesion detection rate than MIBG SPECT/CT in neuroblastoma patients. 69,70 Ongoing and future research will be instrumental in characterizing the use and limitations of MIBG PET, potentially leading to clinical approval.…”

Section: Novel Pet Agentsmentioning

confidence: 99%

“…The novel PET radiotracers 124 I-MIBG and 18 F-MIBG, which have the same biodistribution as 123/131 I-MIBG, are being investigated for imaging cancers, which overexpress the norepinephrine transporter such as PPGL. Initial studies report that MIBG PET/CT has a higher lesion detection rate than MIBG SPECT/CT in neuroblastoma patients 69,70 . Ongoing and future research will be instrumental in characterizing the use and limitations of MIBG PET, potentially leading to clinical approval.…”

Section: Molecular Imaging Of Ppglmentioning

confidence: 99%

Theranostics in Neuroendocrine Tumors

Mallak,

O'Brien,

Pryma

et al. 2024

Cancer J

View full text Add to dashboard Cite

Neuroendocrine tumors (NETs) are rare tumors that develop from cells of the neuroendocrine system and can originate in multiple organs and tissues such as the bowels, pancreas, adrenal glands, ganglia, thyroid, and lungs. This review will focus on gastroenteropancreatic NETs (more commonly called NETs) characterized by frequent somatostatin receptor (SSTR) overexpression and pheochromocytomas/paragangliomas (PPGLs), which typically overexpress norepinephrine transporter. Advancements in SSTR-targeted imaging and treatment have revolutionized the management of patients with NETs. This comprehensive review delves into the current practice, discussing the use of the various Food and Drug Administration–approved SSTR-agonist positron emission tomography tracers and the predictive imaging biomarkers, and elaborating on 177Lu-DOTATATE peptide receptor radionuclide therapy including the evolving areas of posttherapy imaging practices and peptide receptor radionuclide therapy retreatment. SSTR-targeted imaging and therapy can also be used in patients with PPGL; however, this patient population has demonstrated the best outcomes from norepinephrine transporter-targeted therapy with 131I-metaiodobenzylguanidine. Metaiodobenzylguanidine theranostics for PPGL will be discussed, noting that in 2024 it became commercially unavailable in the United States. Therefore, the use and reported success of SSTR theranostics for PPGL will also be explored.

show abstract

“…8 Recent publications have shown that 18 F-MFBG PET/CT has significant advantage over conventional 123 I-MIBG SPECT/CT in the evaluation of neuroblastoma. 9,10 The most common locations of metastases from neuroblastoma are bone or bone marrows. Neuroblastomas to the brain usually occur after there had been widespread metastases elsewhere.…”

mentioning

confidence: 99%

“…In patients with metastatic pheochromocytomas and paragangliomas, MFBG PET/CT offers a similar or slightly better accuracy than DOTATATE PET/CT 8. Recent publications have shown that 18 F-MFBG PET/CT has significant advantage over conventional 123 I-MIBG SPECT/CT in the evaluation of neuroblastoma 9,10. The most common locations of metastases from neuroblastoma are bone or bone marrows.…”

mentioning

confidence: 99%

18F-MFBG PET/CT and MRI in Identifying Brain Metastases in a Posttreatment Neuroblastoma Patient

Wang,

Li,

Zhuang

et al. 2024

Clin Nucl Med

Self Cite

View full text Add to dashboard Cite

A 7-year-old girl with known brain metastasis from neuroblastoma developed new onset of severe headache. A brain MRI confirmed known metastasis in the right frontal lobe of the brain without new abnormalities. The patient was enrolled in a clinical trial using 18F-MFBG PET/CT to evaluate patients with neuroblastoma. The images confirmed abnormal activity in the known lesion in the right frontal lobe. In addition, the PET showed additional foci of abnormal activity in the left cerebellopontine region. A follow-up brain MRI study acquired 4 months later revealed abnormal signals in the same region.

show abstract

[18F]MFBG PET/CT outperforming [123I]MIBG SPECT/CT in the evaluation of neuroblastoma

Cited by 15 publications

References 37 publications

Gastroesophageal Reflux Revealed by 18F-MFBG PET/CT

Gastroesophageal Reflux Revealed by 18F-MFBG PET/CT

Theranostics in Neuroendocrine Tumors

18F-MFBG PET/CT and MRI in Identifying Brain Metastases in a Posttreatment Neuroblastoma Patient

Contact Info

Product

Resources

About